Ive Oncology Group Functionality Status (ECOG PS) score (0 or two), NLR (five orIve Oncology

November 29, 2023

Ive Oncology Group Functionality Status (ECOG PS) score (0 or two), NLR (five or
Ive Oncology Group Functionality Status (ECOG PS) score (0 or two), NLR (five or 5), platelet to Wnt4, Human (HEK293, C-hFc) lymphocyte ratio (PLR) (150 or 150), levels of carbohydrate Hepcidin/HAMP Protein Species antigen 199 (CA19-9, 1000 or 1000 UmL), carcinoembryonic antigen (CEA, 5 or five ngmL), C-reactive protein (CRP, 0.five or 0.five mgdL), lactate dehydrogenase (LDH, 250 or 250 IUL), hemoglobin (10 or 10 gdL), and albumin (three.five or three.five gdL).Patients and MethodsPatients and treatmentUsing a prospective cohort database technique (CyberOncology Cyber Laboratory Inc., Tokyo, Japan) [19] and electronic healthcare charts, we retrieved the clinical information of 269 consecutive individuals with pathologically confirmed pancreatic ductal adenocarcinoma who received at the very least two cycles of palliative first-line chemotherapy at Kyoto University Hospital (Kyoto, Japan) among January 2006 and December 2012. In principle, NLR was calculated utilizing the neutrophils and lymphocytes counts obtained on the exact same day of chemotherapy. If blood test was not performed around the exact same day of chemotherapy, we substituted the data obtained within 2 days of chemotherapy. Sixteen circumstances had been excluded from this study for the reason that a set of NLR values prior to the first and second chemotherapy cycles was not readily available, and 252 individuals had been ultimatelyStatistical analysisBaseline patient qualities had been compared making use of the v2 test or Fisher’s precise test for dichotomous variables or the Mann hitney U test for continuous variables. The time for you to therapy failure (TTF) was calculated in the date of palliative chemotherapy initiation and terminated on the date of palliative chemotherapy discontinuation for various causes, including treatment toxicity, illness progression, or patient withdrawal. Overall survival (OS) was calculated in the date of palliative chemotherapy initiation and terminated on the date of death for any purpose or censored around the final follow-up check out. TTF and OS had been estimated working with the Kaplan eier system, and differences had been compared using log-rank tests. Cox2014 The Authors. Cancer Medicine published by John Wiley Sons Ltd.NLR for Predicting Palliative ChemotherapyP. Xue et al.Table 1. Baseline characteristics. Total (n = 252) NLR 5 (n = 212) NLR 5 (n = 40)Variables Age 65 65 Gender Male Female PS score 0 2 Distant metastasis Yes No Principal tumor location Head Body and tail The status of recurrent or unresectable Recurrent Unresectable Palliative initial line Gemcitabine monotherapy Gemcitabine and S-1 S-1 monotherapy Gemcitabine and Erlotinib CA19-9 (UmL) 1000 1000 CEA (ngmL) 5 5 CRP (mgdL) 0.five 0.5 LDH (IUL) 250 250 Hemoglobin (gdL) ten ten Albumin (gdL) 3.5 3.five PLR 150 150 TB (mgdL) Median Variety AST (IUL) Median Variety ALT (IUL) Median Variety Creatinin (mgdL) Median RangeP-value148 (58.7 ) 104 (41.three ) 133 (52.eight ) 119 (47.2 ) 242 (96.0 ) ten (4.0 ) 184 (73.0 ) 68 (27.0 ) 146 (57.9 ) 106 (42.1 ) 73 (29.0 ) 179 (71.0 ) 156 85 9 2 (61.9 ) (33.7 ) (3.six ) (0.eight )122 (57.five ) 90 (42.five ) 110 (51.9 ) 102 (48.1 ) 204 (96.2 ) 8 (3.8 ) 152 (71.7 ) 60 (28.three ) 127 (59.9 ) 85 (40.1 ) 64 (30.two ) 148 (69.8 ) 130 73 7 two (61.three ) (34.4 ) (3.three ) (1.0 )26 (65.0 ) 14 (35.0 ) 23 (57.five ) 17 (42.five ) 38 (95.0 ) 2 (five.0 ) 32 (80.0 ) 8 (20.0 ) 19 (47.5 ) 21 (52.five ) 9 (22.5 ) 31 (77.five ) 26 (65.0 ) 12 (30.0 ) two (five.0 ) 0 26 (65.0 ) 14 (35.0 ) 19 (47.5 ) 21 (52.five ) 16 (40.0 ) 24 (60.0 ) 29 (72.five ) 11 (27.five ) 6 (15.0 ) 34 (85.0 ) 26 (65.0 ) 14 (35.0 ) 38 (95.0 ) 2 (5.0 ) 0.7 0.three.2 25 1122 24 750 0.7 0.4.0.0.0.0.0.0.0.196 (77.8 ) 56 (22.2 ) 145 (57.five ) 107 (42.five ) 175 (69.4.